Migraine (Prophylaxis) | Treatment Algorithms | Claims Data Analysis | US | 2022

According to Clarivate epidemiology, more than 30 million people in the United States experience migraines. Migraine prophylaxis, despite being underused, is a core treatment approach to reduce the frequency, severity, and duration of migraines. Prescription options include a diverse mix of on- and off-label oral drugs—AbbVie / Allergan’s Botox, four anti-CGRP MAbs, and most recently, two oral CGRP antagonists. Prophylaxis is both individualized and dynamic, as physicians adjust regimens to improve outcomes and/or avoid side effects. Understanding this patient journey provides needed context for new and existing players as the prophylactic market becomes increasingly competitive.


  • What patient shares do key brands and generics garner by line of therapy in migraine patients initiating prophylaxis? What are the quarterly trends in prescribing among recently treated and prophylactically naive migraine patients?
  • What is the dynamic between anti-CGRP MAbs? How has Lundbeck’s Vyepti been integrated into the treatment algorithm?
  • What percentage of prophylactically naive migraine patients began drug therapy during our two-year prescription-tracking period? What percentage of patients progress to later lines of therapy, and how quickly do they progress?
  • What percentage of migraine patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among prophylactically treated migraine patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States.

Key companies: Amgen / Novartis, Eli Lilly, Teva, Lundbeck, AbbVie / Allergan, Supernus Pharmaceuticals, Upsher-Smith, and Janssen-Cilag.

Key drugs: Aimovig, Emgality, Ajovy, Vyepti, Botox, Trokendi XR, Qudexy XR, topiramate IR/XR, propranolol, amitriptyline, verapamil.


The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Login to access report